Evidence map›Paper›PMID 41276768›Full record

Trial reportAnnals of surgical oncology2026

Axillary Management and Outcomes After Neoadjuvant Endocrine Therapy in the Randomized PELOPS Trial.

Anna Weiss, Qingchun Jin, Nabihah Tayob, Eileen Wrabel, Michelle DeMeo, Jamie Carter, Michael Constantine, Meredith Faggen, Caroline Block, Mary Anne Fenton and 9 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02764541 (Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02764541 phase2active not recruitingnot on this map

Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS): A Randomized Phase II Study of Palbociclib With Letrozole Versus Letrozole Alone for Invasive Lobular Carcinoma and Invasive Ductal Carcinoma

TypeinterventionalSponsorDana-Farber Cancer InstituteRan2016 to 2031Enrolled195ConditionsBreast CancerArmsLetrozole, Tamoxifen, Palbociclib, Endocrine Therapy
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Anna WeissDivision of Surgical Oncology, Department of Surgery, University of Rochester Medical Center, Rochester, NY, USA. Anna_weiss@urmc.rochester.edu.
Qingchun JinDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Nabihah TayobDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Eileen WrabelBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Michelle DeMeoBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Jamie CarterBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Michael ConstantineBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Meredith FaggenBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Caroline BlockBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Mary Anne FentonDivision of Oncology, Lifespan Cancer Institute, Providence, RI, USA.
K M Steve LoDivision of Medical Oncology, Stamford Health, Stamford, CT, USA.
Thomas OpenshawEastern Maine Medical Center, Bangor, ME, USA.
Denise YardleyDepartment of Medical Oncology, Sarah Cannon Research Institute, Nashville, TN, USA.
Laura KennedyDivision of Medical Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
Isabelle BedrosianDepartment of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Elizabeth A MittendorfDivision of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Rinath JeselsohnBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Otto Metzger FilhoBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Tari A KingDivision of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundData to inform surgical management of the axilla after neoadjuvant endocrine therapy (NET) are limited. Here we report nodal status, surgical procedure, and outcomes among patients enrolled between 2016 and 2020 in the Palbociclib and Endocrine therapy for LObular breast cancer Preoperative Study (NCT02764541).

methodsWomen with hormone receptor-positive, HER2-negative tumors > 1.5 cm, any cN, were randomized 2:1 to NET ± palbociclib for 24 weeks. Axillary surgery (sentinel lymph node biopsy [SLNB] ± axillary dissection [ALND]) and nodal evaluation (H&E ± IHC) were not specified in the protocol. Pathologic node-positive (ypN+) rates, local-regional recurrence-free interval (LRRFI), and breast cancer-specific survival (BCSS), compared by univariate Cox proportional hazards, were prespecified exploratory endpoints.

resultsA total of 188 patients were analyzed (128 treated with NET + palbociclib, 60 NET), median age 56.5 years (interquartile range [IQR] 50-66). 82 (43.6%) had lobular histology, 99 (52.7%) were cN0, 84 (44.7%) cN+, and 5 (2.6%) cN unknown. Of cN+ patients with known ypN, nodal pathologic complete response rates were 10.9% (6/55) after NET + palbociclib and 13.6% (3/22) after NET. Among 108 ypN+ patients, 26 (24.1%) underwent SLNB, 82 (75.9%) ALND, and 99 (91.7%) radiation. At 4.65 years (IQR 3.66-5.56) median follow-up, 3-year LRRFI for ypN+ patients treated with SLNB only was 96% (88.6%, 100%) and ALND was 97.4% (93.9%, 100.0%), p = 0.6; 3-year BCSS for SLNB was 96.0% (88.6%, 100.0%) and ALND was 100.0% (100%, 100%), p = 0.9.

conclusionsThe addition of palbociclib to NET did not impact pathologic nodal outcomes. Among those with ypN+ disease, neither LRRFI nor BCSS appears to be impacted by performance of ALND.

trial registrationclinicaltrials.gov, NCT02764541.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarcinoma, LobularLymph Node ExcisionNeoadjuvant TherapyNeoplasm Recurrence, LocalAgedAntineoplastic Agents, HormonalAxillaFemaleFollow-Up StudiesHumansMiddle AgedPiperazinesPrognosisPyridinesAntineoplastic Agents, HormonalpalbociclibPiperazinesPyridinesReceptors, EstrogenAxillary lymph node dissectionAxillary managementAxillary surgeryBreast cancerClinical trialNeoadjuvant endocrine therapyOutcomes

Identifiers

PMID41276768

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.